Inhaled CNS Therapeutics
|出版商||Greystone Research Associates||商品編碼||304994|
Neurological disorders are highly prevalent worldwide. And while mental and neurological disorders are responsible for about one per cent of deaths, they account for almost 11 per cent of disease burden globally. As the absolute number and relative percentage of people age 65 and older increases, the goal of reversing or ameliorating the effects of neurological disease becomes critical to easing a looming financial and human burden that these diseases will impose on society. Current research is showing potential in increasing the quality of life and delaying cognitive decline for those diagnosed with neurological disease. In addition to the handful of FDA-approved inhaled CNS products, several companies are currently pursuing a range of APIs in inhalation device delivery systems that target neurological and CNS conditions. While none of these development-stage candidates is curative, the benefits they can offer in terms of patient ease-of-use, product safety and overall quality-of-care are expected to result in reduced morbidity and more effective symptom management for afflicted patients.